170728-75-3

Upstream product

• 150598-37-1 trifluoromethanesulfonic acid 2-oxo-2H-1-benzopyran-5-yl ester 
• 6093-67-0 5-hydroxycoumarin 

Downstream Products

• 170728-76-4 rac-(E)-4-[2-(3-Methoxy-3-oxo-1-propenyl)-3-[6-[(tetrahydro-2H-pyran-2-yl)oxy]-1-hexynyl]phenoxy]butanoic Acid Ethyl Ester 
• 150598-41-7 rac-2-(5-ethoxy-5-oxopentyloxy)-6-[6-[(tetrahydro-2H-pyran-2-yl)oxy]hexyl]benzenepropanoic acid methyl ester 
• 150598-40-6 rac-(E)-5-[2-(3-methoxy-3-oxo-1-propenyl)-3-[6-[(tetrahydro-2H-pyran-2-yl)oxy]-1-hexynyl]phenoxy]pentanoic acid ethyl ester 

Relevant academic research and scientific papers

Carboxylic acid Leukotriene B4 antagonists

The invention relates to compounds selected from the group consisting of the formulas: STR1 wherein R2 and Ph are as described herein. These compounds are potent leukotriene B4 antagonists and are therefore useful in the treatment of inflammatory diseases.

CARBOXYLIC ACID LEUKOTRIENE B4 ANTAGONISTS

Compounds of the formula STR1 wherein X is O or CH 2 ; Y is O,--CH 2--CH 2,--CH=CH--,--C C--, or--OCH 2 C 6 H 4--;Z is--CH 2--CH 2--,--CH=CH--or--C C--;f, h, k, m and t, independently, are 0 or 1;n is an integer from 1 to 12; R 1 is hydrogen, lower alkyl, lower alkenyl, cycloalkyl, or aralkyl; andA is B or--O--B, wherein B is a mono-, di-or tricyclic aromatic or heteroaromatic moiety substituted by the group--COR 2,--(O) t--(W) s--COR 2 or--(CH=CH) p COR 2 and which may also contain up to 4 additional substituents selected, independently, from the group consisting of halogen, cyano, lower alkyl, lower alkoxy, sulfonamido, alkanoyl, aroyl,--(Q) k--(W) s'--E or--(Q) k--(W) s"--C 6 H 4--(W) s'"--E, provided that no more than one of said substituents is--(Q) k--(W) s'--E or--(Q) k--(W). sub.s"--C 6 H 4--(W) s'"--E, and wherein E is COR 2 or R 2, W is--CR 3 R 4--, Q is O or carbonyl, p is an integer from 1 to 2, s and s', independently, are an integer from 1-12, s" and s'", independently, are an integer from 0 to 12, C 6 H 4 is a 1,2-, 1,3-, or 1,4-phenylene moiety, and R 2 is hydroxy, lower alkoxy or NR 3 R 4, wherein R 3 and R 4, each occurrence, independently, are hydrogen or lower alkyl,their geometric and optical isomers and, when R 2 is hydroxy, pharmaceutically acceptable salts thereof with bases. The compounds of formula I are potent leukotriene B 4 antagonists and are therefore useful in the treatment of inflammatory diseases, such as psoriasis, inflammatory bowel disease, asthma, allergy, arthritis, dermatitis, gout, pulmonary disease, ischemia/reperfusion injury, and trauma induced inflammation, such as spinal cord injury. "